Exelixis Inc Cost of Revenue
Exelixis Inc (EXEL) reported Cost of Revenue of $20.66 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Exelixis Inc cost of goods and services sold for the quarter ending 2026-07-03 was $20.66M, a 6.10% increase year-over-year.
- Exelixis Inc cost of goods and services sold for the quarter ending 2026-04-03 was $19.95M, a 4.07% increase year-over-year.
- Exelixis Inc cost of goods and services sold for the quarter ending 2026-01-02 was $26.48M, a 32.64% increase year-over-year.
- Exelixis Inc cost of goods and services sold for the quarter ending 2025-10-03 was $18.57M, a 7.19% increase year-over-year.
- Exelixis Inc cost of goods and services sold for fiscal 2026 was $83.70M, a 9.82% increase from fiscal 2025.
- Exelixis Inc cost of goods and services sold for fiscal 2025 was $76.22M, a 5.06% increase from fiscal 2023.
- Exelixis Inc cost of goods and services sold for fiscal 2023 was $72.55M, a 25.28% increase from fiscal 2022.
- Exelixis Inc cost of goods and services sold for fiscal 2022 was $57.91M, a 9.52% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-07-03 | $20.66M 10-Q · filed 2026-08-05 | $40.61M 10-Q · filed 2026-08-05 | $67.09M derived: sum of 3 quarters · filed 2026-08-05 | $85.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $19.95M 10-Q · filed 2026-05-05 | $46.43M derived: sum of 2 quarters · filed 2026-05-05 | $65.01M derived: sum of 3 quarters · filed 2026-05-05 | $84.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $26.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $45.05M derived: sum of 2 quarters · filed 2026-02-10 | $64.53M derived: sum of 3 quarters · filed 2026-08-05 | $83.70M 10-K · filed 2026-02-10 |
| 2025-10-03 | $18.57M 10-Q · filed 2025-11-04 | $38.04M derived: sum of 2 quarters · filed 2026-08-05 | $57.22M 10-Q · filed 2025-11-04 | $77.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $19.47M 10-Q · filed 2026-08-05 | $38.64M 10-Q · filed 2026-08-05 | $58.61M derived: sum of 3 quarters · filed 2026-08-05 | $75.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $19.17M 10-Q · filed 2026-05-05 | $39.14M derived: sum of 2 quarters · filed 2026-05-05 | $56.47M derived: sum of 3 quarters · filed 2026-05-05 | $74.13M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $19.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $37.29M derived: sum of 2 quarters · filed 2026-02-10 | $54.96M derived: sum of 3 quarters · filed 2026-02-10 | $76.22M 10-K · filed 2026-02-10 |
| 2024-09-27 | $17.33M 10-Q · filed 2025-11-04 | $34.99M derived: sum of 2 quarters · filed 2025-11-04 | $56.25M 10-Q · filed 2025-11-04 | $78.00M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $17.67M 10-Q · filed 2025-07-28 | $38.92M 10-Q · filed 2025-07-28 | $60.68M derived: sum of 3 quarters · filed 2026-02-10 | $79.45M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $21.26M 10-Q · filed 2025-05-13 | $43.01M derived: sum of 2 quarters · filed 2026-02-10 | $61.78M derived: sum of 3 quarters · filed 2026-02-10 | $79.49M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $21.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $40.53M derived: sum of 2 quarters · filed 2026-02-10 | $58.23M derived: sum of 3 quarters · filed 2026-02-10 | $72.55M 10-K · filed 2026-02-10 |
| 2023-09-29 | $18.77M 10-Q · filed 2024-10-29 | $36.48M derived: sum of 2 quarters · filed 2024-10-29 | $50.79M 10-Q · filed 2024-10-29 | $66.71M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $17.70M 10-Q · filed 2024-08-06 | $32.02M 10-Q · filed 2024-08-06 | $47.94M derived: sum of 3 quarters · filed 2025-02-11 | $63.24M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $14.31M 10-Q · filed 2024-04-30 | $30.23M derived: sum of 2 quarters · filed 2025-02-11 | $45.54M derived: sum of 3 quarters · filed 2025-02-11 | $59.02M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $15.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $31.23M derived: sum of 2 quarters · filed 2025-02-11 | $44.71M derived: sum of 3 quarters · filed 2025-02-11 | $57.91M 10-K · filed 2025-02-11 |
| 2022-09-30 | $15.30M 10-Q · filed 2023-11-01 | $28.79M derived: sum of 2 quarters · filed 2023-11-01 | $41.99M 10-Q · filed 2023-11-01 | $54.91M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $13.48M 10-Q · filed 2023-08-01 | $26.68M 10-Q · filed 2023-08-01 | $39.60M derived: sum of 3 quarters · filed 2024-02-06 | $51.48M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $13.20M 10-Q · filed 2023-05-09 | $26.12M derived: sum of 2 quarters · filed 2024-02-06 | $37.99M derived: sum of 3 quarters · filed 2024-02-06 | $52.88M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $12.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $24.79M derived: sum of 2 quarters · filed 2024-02-06 | $39.67M derived: sum of 3 quarters · filed 2024-02-06 | $52.87M 10-K · filed 2024-02-06 |
| 2021-10-01 | $11.87M 10-Q · filed 2022-11-01 | $26.76M derived: sum of 2 quarters · filed 2022-11-01 | $39.96M 10-Q · filed 2022-11-01 | $48.99M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $14.88M 10-Q · filed 2022-08-09 | $28.08M 10-Q · filed 2022-08-09 | $37.12M derived: sum of 3 quarters · filed 2023-02-07 | $45.84M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $13.20M 10-Q · filed 2022-05-10 | $22.23M derived: sum of 2 quarters · filed 2023-02-07 | $30.96M derived: sum of 3 quarters · filed 2023-02-07 | $40.18M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $17.76M derived: sum of 2 quarters · filed 2023-02-07 | $26.98M derived: sum of 3 quarters · filed 2023-02-07 | $36.27M 10-K · filed 2023-02-07 |
| 2020-10-02 | $8.72M 10-Q · filed 2021-11-02 | $17.95M derived: sum of 2 quarters · filed 2021-11-02 | $27.23M 10-Q · filed 2021-11-02 | $37.76M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $9.22M 10-Q · filed 2021-08-05 | $18.51M 10-Q · filed 2021-08-05 | $29.03M derived: sum of 3 quarters · filed 2022-02-18 | $36.57M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $9.29M 10-Q · filed 2021-05-06 | $19.81M derived: sum of 2 quarters · filed 2022-02-18 | $27.35M derived: sum of 3 quarters · filed 2022-02-18 | $34.88M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $18.06M derived: sum of 2 quarters · filed 2022-02-18 | $25.60M derived: sum of 3 quarters · filed 2022-02-18 | $33.10M 10-K · filed 2022-02-18 |
| 2019-09-27 | $7.54M 10-Q · filed 2020-11-05 | $15.08M derived: sum of 2 quarters · filed 2020-11-05 | $22.58M 10-Q · filed 2020-11-05 | $29.93M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $7.54M 10-Q · filed 2020-08-06 | $15.04M 10-Q · filed 2020-08-06 | $22.39M derived: sum of 3 quarters · filed 2020-08-06 | $29.75M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | $7.50M 10-Q · filed 2020-05-05 | $14.85M derived: sum of 2 quarters · filed 2020-05-05 | $22.21M derived: sum of 3 quarters · filed 2020-05-05 | $28.21M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $14.71M derived: sum of 2 quarters · filed 2020-02-25 | $20.71M derived: sum of 3 quarters · filed 2020-02-25 | $26.35M 10-K · filed 2021-02-11 |
| 2018-09-28 | $7.36M 10-Q · filed 2019-10-30 | $13.36M derived: sum of 2 quarters · filed 2019-10-30 | $19.00M 10-Q · filed 2019-10-30 | $23.19M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $6.00M 10-Q · filed 2019-07-31 | $11.64M 10-Q · filed 2019-07-31 | $15.83M derived: sum of 3 quarters · filed 2020-02-25 | $20.48M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-30 | $5.64M 10-Q · filed 2019-05-01 | $9.83M derived: sum of 2 quarters · filed 2020-02-25 | $14.49M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-29 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $8.85M derived: sum of 2 quarters · filed 2020-02-25 | $15.07M 10-K · filed 2020-02-25 | |
| 2017-09-29 | $4.66M 10-Q · filed 2018-11-01 | $10.88M 10-Q · filed 2018-11-01 | ||
| 2016-12-30 | $6.55M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |